Scarica l'app Stockscreener
14.22
8.14%
1.07
Dopo l'orario di chiusura:
14.24
0.02
+0.14%
Precedente Chiudi:
$13.15
Aprire:
$13.39
Volume 24 ore:
1.30M
Relative Volume:
0.39
Capitalizzazione di mercato:
$1.19B
Reddito:
-
Utile/perdita netta:
$-15.28M
Rapporto P/E:
-28.10
EPS:
-0.5061
Flusso di cassa netto:
$-32.97M
1 W Prestazione:
+0.99%
1M Prestazione:
-21.87%
6M Prestazione:
+115.13%
1 anno Prestazione:
+261.83%
Intervallo 1D:
$13.31
$14.54
Intervallo di 1 settimana:
$12.95
$14.54
Portata 52W:
$2.54
$26.95
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Nome
Corvus Pharmaceuticals Inc
Settore
Industria
Telefono
(650) 900-4520
Indirizzo
901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA
Compare CRVS vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
14.22 | 1.10B | 0 | -15.28M | -32.97M | -0.5061 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-01-02 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-18 | Iniziato | Oppenheimer | Outperform |
| 2021-12-01 | Ripresa | Jefferies | Buy |
| 2021-05-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-02-10 | Downgrade | Mizuho | Buy → Neutral |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-05-29 | Iniziato | ROTH Capital | Buy |
| 2017-08-24 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | Iniziato | Credit Suisse | Outperform |
| 2016-04-18 | Iniziato | Guggenheim | Buy |
Mostra tutto
Corvus Pharmaceuticals Inc Borsa (CRVS) Ultime notizie
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 8.4% HigherTime to Buy? - MarketBeat
Income Plays: Can Corvus Pharmaceuticals Inc beat the S P 5002026 Volume Leaders & Safe Capital Investment Plans - baoquankhu1.vn
Is Corvus Pharmaceuticals Inc forming a breakout pattern2026 Growth vs Value & Accurate Buy Signal Notifications - baoquankhu1.vn
Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger - MSN
Bond Watch: Will Corvus Pharmaceuticals Inc stock go up in YEAR2026 Levels & Daily Entry Point Trade Alerts - baoquankhu1.vn
Is Corvus Pharmaceuticals’ Expanded US$200 Million ATM Facility Reframing Its Funding Story for CRVS? - Sahm
Growth Recap: Will Corvus Pharmaceuticals Inc outperform tech stocksEarnings Overview Report & Daily Stock Trend Watchlist - baoquankhu1.vn
A Look At Corvus Pharmaceuticals (CRVS) Valuation After Recent Share Price Swings - Sahm
FY2030 Earnings Forecast for CRVS Issued By HC Wainwright - MarketBeat
Corvus outlines cash runway into Q2 2028 and targets mid-2027 Phase II readout for soquelitinib in atopic dermatitis - MSN
Corvus Trials Progress And Cash Raise Reframe Soquelitinib Risk Reward Profile - Sahm
Corvus Pharmaceuticals Expands Equity Sales Capacity to $200 Million - The Globe and Mail
Corvus Pharmaceuticals (NASDAQ:CRVS) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Corvus Pharmaceuticals Bets Big on Soquelitinib Pipeline - TipRanks
CRVS Stock Receives Analyst Rating and Price Target Boost from O - GuruFocus
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Rapid Multi‑Year Share Price Gains - Yahoo Finance
Corvus Pharmaceuticals (NASDAQ:CRVS) Given Outperform Rating at Oppenheimer - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 6.5% After Earnings Miss - MarketBeat
According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), Corvus Pharmaceuticals, Inc. has signed a revised equity distribution agreement. - Bitget
Corvus Pharmaceuticals Expands ATM Equity Program to $200 Million With Jefferies - TradingView
Corvus Pharmaceuticals (NASDAQ: CRVS) launches $200M at-the-market stock program - Stock Titan
Corvus Pharmaceuticals (NASDAQ: CRVS) doubles Jefferies ATM capacity to $200M - Stock Titan
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2025 Earnings Call Transcript - Insider Monkey
Corvus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Corvus Pharmaceuticals (CRVS) files S-3 shelf to offer stock, debt, warrants - Stock Titan
Oppenheimer raises Corvus Pharmaceuticals stock price target to $33 By Investing.com - Investing.com Canada
Corvus: Q4 Earnings Snapshot - theheraldreview.com
Corvus Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Corvus Pharmaceuticals rises on atopic dermatitis trial data By Investing.com - Investing.com Australia
Decoding Corvus Pharmaceuticals Inc (CRVS): A Strategic SWOT Ins - GuruFocus
Corvus: Fourth Quarter Earnings Overview - Bitget
Earnings call transcript: Corvus Pharmaceuticals Q4 2025 Misses EPS Forecast - Investing.com
CRVS: Strong clinical and financial momentum with soquelitinib, supporting pipeline expansion and durability - TradingView
Corvus Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Corvus Pharmaceuticals (NASDAQ:CRVS) Issues Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Corvus Pharmaceuticals 2025 Financial Report: Quarterly & Annual Results | CRVSNews and Statistics - IndexBox
Corvus Pharmaceuticals options imply 7.9% move in share price post-earnings - TipRanks
Corvus Pharmaceuticals rises on atopic dermatitis trial data - Investing.com
CORVUS PHARMACEUTICALS ($CRVS) Releases Q4 2025 Earnings - Quiver Quantitative
Corvus Pharmaceuticals (NASDAQ: CRVS) highlights soquelitinib Phase 3 and Phase 2 trials - Stock Titan
Corvus Pharmaceuticals 10‑K: $0 Revenue, $(0.19) EPS (basic) — net loss $(15.28M) - TradingView
Corvus Pharmaceuticals (NASDAQ: CRVS) posts 2025 results and $189.4M financing boost - Stock Titan
Corvus eczema drug posts positive early data and $189M cash boost - Stock Titan
Corvus Pharmaceuticals earnings on deck after positive trial data By Investing.com - Investing.com South Africa
Corvus Pharmaceuticals earnings on deck after positive trial data - Investing.com
Earnings Scheduled For March 12, 2026 - Benzinga
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Quarterly Earnings: Is Corvus Pharmaceuticals Inc being accumulated by smart money2026 Technical Overview & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Corvus Pharmaceuticals (CRVS) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Corvus Pharmaceuticals (CRVS) soars 212% on impressive eczema therapy study - MSN
Corvus Pharmaceuticals Inc Azioni (CRVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):